

**Announcement 26 March 2010****Coloplast – transactions in connection with share buy-back programme**

As informed in Announcement No. 2/2010 the shareholders in general meeting in December 2009 authorised Coloplast to establish a share buy-back programme of up to DKK 1bn during 2010 and 2011. The first part of DKK 500m will be exercised in the period from 15 February 2010 to 30 September 2010.

Under the programme the following transactions have been executed during the period 22-26 March 2010:

<b>Date</b>	<b>Number of shares</b>	<b>Average buying price</b>	<b>Amount DKK</b>
22.3.2010	7,500	600.70	4,505,250.00
23.3.2010	7,000	599.07	4,193,490.00
24.3.2010	-	0.00	0.00
25.3.2010	14,354	608.47	8,733,978.38
26.3.2010	5,771	609.97	3,520,136.87
<b>Accumulated until now under the programme</b>	<b>282,176</b>	<b>615.76</b>	<b>173,751,589.37</b>

Henceforth, Coloplast owns 2,317,521 own B shares of DKK 5 equal to 5.15% of the company's total share capital.

Share buy-back in the amount of DKK 326,248,410.63 remains under the first part of the programme.

## **For further information, please contact**

### **Investors and analysts**

Lene Skole  
Executive Vice President, CFO  
Tel. +45 4911 1700

Ian S.E. Christensen  
Director of Investor Relations  
Tel. +45 4911 1800/+45 4911 1301  
Email: dkisec@coloplast.com

### **Press and the media**

Morten Sørensen  
Media Relations Manager  
Tel. +45 4911 2632  
Email: dkmoso@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2010-03 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology and Continence Care and Wound and Skin Care. We operate globally and employ more than 7,000 people.